166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel

S. Thompson, B. Ballard, Z. Jiang, E. Revskaya, N. Sisay, W. H. Miller, C. S. Cutler, E. Dadachova, L. C. Francesconi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: An approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter 188Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (Emax>1.5MeV) emission properties. Methods: 6D2 was radiolabeled with longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed. Results: When labeled with the longer lived 90Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by 166Ho-6D2 was very similar to the previously reported therapy results for 188Re-6D2. In addition, 166Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. Conclusions: 166Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of 166Ho to deliver the tumoricidal absorbed dose to the tumor. Further investigation of this radionuclide for RIT of melanoma is warranted.

Original languageEnglish (US)
Pages (from-to)276-281
Number of pages6
JournalNuclear Medicine and Biology
Volume41
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Melanoma
Radiotherapy
Monoclonal Antibodies
Poisons
Melanins
Radioisotopes
Neoplasms
Therapeutic Uses
Radioimmunotherapy
Half-Life
Experimental Melanomas
Nude Mice
Antibodies
Therapeutics
Growth
Cell- and Tissue-Based Therapy
Immunoglobulin M
Serum

Keywords

  • Antibody
  • Melanoma
  • Radioisotopes
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Thompson, S., Ballard, B., Jiang, Z., Revskaya, E., Sisay, N., Miller, W. H., ... Francesconi, L. C. (2014). 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel. Nuclear Medicine and Biology, 41(3), 276-281. https://doi.org/10.1016/j.nucmedbio.2013.12.015

166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma : Comparison with 188Re radiolabel. / Thompson, S.; Ballard, B.; Jiang, Z.; Revskaya, E.; Sisay, N.; Miller, W. H.; Cutler, C. S.; Dadachova, E.; Francesconi, L. C.

In: Nuclear Medicine and Biology, Vol. 41, No. 3, 03.2014, p. 276-281.

Research output: Contribution to journalArticle

Thompson, S, Ballard, B, Jiang, Z, Revskaya, E, Sisay, N, Miller, WH, Cutler, CS, Dadachova, E & Francesconi, LC 2014, '166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel', Nuclear Medicine and Biology, vol. 41, no. 3, pp. 276-281. https://doi.org/10.1016/j.nucmedbio.2013.12.015
Thompson, S. ; Ballard, B. ; Jiang, Z. ; Revskaya, E. ; Sisay, N. ; Miller, W. H. ; Cutler, C. S. ; Dadachova, E. ; Francesconi, L. C. / 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma : Comparison with 188Re radiolabel. In: Nuclear Medicine and Biology. 2014 ; Vol. 41, No. 3. pp. 276-281.
@article{429e2175c7124d6a8ea724093ced3223,
title = "166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel",
abstract = "Introduction: An approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter 188Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (Emax>1.5MeV) emission properties. Methods: 6D2 was radiolabeled with longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed. Results: When labeled with the longer lived 90Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by 166Ho-6D2 was very similar to the previously reported therapy results for 188Re-6D2. In addition, 166Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. Conclusions: 166Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of 166Ho to deliver the tumoricidal absorbed dose to the tumor. Further investigation of this radionuclide for RIT of melanoma is warranted.",
keywords = "Antibody, Melanoma, Radioisotopes, Radiotherapy",
author = "S. Thompson and B. Ballard and Z. Jiang and E. Revskaya and N. Sisay and Miller, {W. H.} and Cutler, {C. S.} and E. Dadachova and Francesconi, {L. C.}",
year = "2014",
month = "3",
doi = "10.1016/j.nucmedbio.2013.12.015",
language = "English (US)",
volume = "41",
pages = "276--281",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma

T2 - Comparison with 188Re radiolabel

AU - Thompson, S.

AU - Ballard, B.

AU - Jiang, Z.

AU - Revskaya, E.

AU - Sisay, N.

AU - Miller, W. H.

AU - Cutler, C. S.

AU - Dadachova, E.

AU - Francesconi, L. C.

PY - 2014/3

Y1 - 2014/3

N2 - Introduction: An approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter 188Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (Emax>1.5MeV) emission properties. Methods: 6D2 was radiolabeled with longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed. Results: When labeled with the longer lived 90Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by 166Ho-6D2 was very similar to the previously reported therapy results for 188Re-6D2. In addition, 166Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. Conclusions: 166Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of 166Ho to deliver the tumoricidal absorbed dose to the tumor. Further investigation of this radionuclide for RIT of melanoma is warranted.

AB - Introduction: An approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter 188Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (Emax>1.5MeV) emission properties. Methods: 6D2 was radiolabeled with longer lived β emitters 90Y and 166Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed. Results: When labeled with the longer lived 90Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by 166Ho-6D2 was very similar to the previously reported therapy results for 188Re-6D2. In addition, 166Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. Conclusions: 166Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the 90Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of 166Ho to deliver the tumoricidal absorbed dose to the tumor. Further investigation of this radionuclide for RIT of melanoma is warranted.

KW - Antibody

KW - Melanoma

KW - Radioisotopes

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84893970954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893970954&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2013.12.015

DO - 10.1016/j.nucmedbio.2013.12.015

M3 - Article

C2 - 24533987

AN - SCOPUS:84893970954

VL - 41

SP - 276

EP - 281

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 3

ER -